The pharmaceutical industry is pushing back against Governor Cuomo's prescription drug price control proposal, arguing that it would lead to cuts in research. And they are pointing the finger at insurance companies and companies known as pharmacy benefit managers for the high costs paid by patients. Peter Pitts is a former FDA Associate Commissioner for External Relations and is now President of the Center for Medicine in the Public Interest.
Pharmaceutical Industry Raises Issue with Cuomo's Drug Price Control Proposal
RECENT NEWS
New JCI Viewpoint: FDA Must Rethink How It Evaluates Precision Medicines for Rare Diseases
Authors argue that rare disease innovation requires learning more from fewer patients—not enrolling more patients... Read more
Troubling Trends: Systemic Practices in Texas' Non-Profit Hospitals That Inflate Health Care Costs
Texas has an opportunity to lead rather than react. Better measurement would strengthen public confidence without diminis... Read more
PROTECTING THE U.S. PHARMACEUTICAL SUPPLY CHAIN: A PATH FORWARD
How proactive FDA policies can help strengthen the American pharmaceutical supply chain of essential medicines, create jo... Read more